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2012.10.0Abstract Background: In spite of the numerous publications of dosimetric comparison of inten-
sity modulated radiotherapy (IMRT) versus conventional radiotherapy in pediatrics, few data exist
regarding clinical use of IMRT and its potential late effects.
Procedure: Pediatric neuroblastoma patients treated between November 2008 and October 2010
with IMRT were reviewed. Treatment plans, clinical, laboratory and radiological data at the last
follow up date were evaluated.
Results: Thirteen patients received IMRT. The mean age was 4.9 ± 2 years. The radiation dose
ranged from 21 to 25.5 Gy with a mean dose of 24.06 Gy. The mean liver dose was 9.81 Gy. The
V8 of the liver was 51 ± 20%, and the V15 of the liver was 21 ± 12%. V18 of the right and left
kidneys were 32 ± 27% and 23 ± 18% respectively. The minimum and maximum vertebral point
doses were 12.82 and 24.87 Gy respectively. The IMRT treatment was well tolerated in terms of
acute toxicity. At 26 months follow up, second malignancy and skeletal asymmetry were not noted,
and the liver and kidney functions showed no signiﬁcant abnormalities.
Conclusions: The use of IMRT in pediatric neuroblastoma confers higher target conformality with
better sparing of the kidneys and it did not show any considerable short term side effects.
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01Introduction
The use of radiation therapy (RT) either preceding or follow-
ing bone marrow transplantation in high risk neuroblastoma
(NB) has been shown to decrease local recurrence rates [1,2].
Studies that incorporated local RT with autologous stem cell
transplant have shown excellent local control rates above
80% [3]. A study from the Children’s Cancer Group showed
a dose–response relationship with respect to local control, with
20 Gy to the primary site having a better locoregional control
rate compared to 10 Gy [4].and hosting by Elsevier B.V. Open access under CC BY-NC-ND license.
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doses in the range of 21–36 Gy. These are doses that usually
approach, sometimes exceed, the kidney tolerance dose [5].
NB tumors are often located in the midline and paraspinal re-
gions, thus encroaching on one or both kidneys. The problem
is compounded by the use of cisplatin chemotherapy, a known
nephrotoxic agent, and RT dose to the kidneys must be kept to
the minimum to avoid renal injury.
IMRT has been recently used in the treatment of pediatric
cancer and has the potential to reduce the RT dose to the or-
gans at risk (OAR) adjacent to the tumor, at the expense of an
increase in the normal tissues volume exposed to low RT doses
[6]. Despite IMRT has been widely used in many tumor sites in
adults like head and neck cancer [7] and prostate cancer [8], its
use in the pediatric ﬁeld remains unclear, as there is substantial
lack of knowledge of the potential late side effects and toxicity,
particularly the risk for second malignant tumors (SMT) in
this young age group.
At King Faisal Specialist Hospital and Research Center
(KFSH&RC), we have started to use IMRT in the treatment
of abdominal NB since 2008, in order to reduce the RT dose
to the kidneys. We identiﬁed 13 NB patients treated with
IMRT. To the best of our knowledge, this is the largest pub-
lished series of IMRT treated NB patients from a single insti-
tution. Most of other published series included IMRT-
dosimetric comparisons on virtual planning rather than actu-
ally IMRT-treated patients.
The aim of this work is to review and evaluate the IMRT
plan, assess the dose to the critical structures, and report treat-
ment toxicities in this young group of patients.
Materials and methods
Throughout the period from November 2008 to October 2010,
patients treated at our center for abdominal NB were reviewed
to select patients treated by IMRT. For each patient the plan
was evaluated regarding the total dose, the target coverage, the
dose to the kidneys, liver, vertebral body and the low dose to
normal tissues.
The patients were treated according to a modiﬁed COG
protocol 3891 for high risk NB with 6 cycles of induction che-
motherapy followed by surgical resection. This was followed
by consolidation myelo-ablative chemotherapy, autologous
stem cell transplant (ASCT), and localized abdominal RT. In
the early years, total body irradiation (TBI) was used as a part
of the pre-conditioning regimen, which was later changed to
chemotherapy only-based conditioning regime. Because of
the young age, most of the children received radiation treat-
ment under general anesthesia (GA).
The selection of the optimal RT technique was based on the
decision of the treating physician. The IMRT plan was com-
pared with the 3DCRT-plan, and IMRT treatment was imple-
mented when the 3D-plan could not achieve the required RT
dose constraints, namely in terms of renal dose. The target
dose ranged from 21 to 24 Gy for completely resected tumors,
while higher doses were prescribed for gross residual disease.
The gross tumor volume (GTV) was contoured on the axial
slices based on the preoperative post-chemotherapy CT scan,
and the planning CT. An additional 1.5 cm margin was added
to generate the clinical target volume (CTV). This margin was
then edited to include only 2 mm of the kidneys and the liver.Finally, the CTV was expanded by 10 mm margin cranio-cau-
dally, and by 3 mm in the lateral and antero–posterior direc-
tions to generate the planning target volume [PTV]. A plan
was accepted if at least 99% of the PTV was covered by the
95% isodose volume, and maximum hot spots were <110%.
For the OAR, the primary objective criteria entailed more than
80% of at least one kidney received less that 18 Gy, and less
than 50% of the liver volume received more than 8 Gy
[V8 Gy], and the volume of the liver receiving more than
15 Gy [V15 Gy] was less than 25%.
The vertebral body was marked as a secondary target vol-
ume aiming at delivering as much homogeneous dose as possi-
ble within the bony tissue of the adjacent vertebrae with a
minimum dose of 15 Gy and a maximum dose as low as pos-
sible so as to avoid potential asymmetric skeletal growth in
the future.
Treatment was delivered using Linac 6–10 Mv. Cone beam
CT (CBCT) was regularly done in the ﬁrst 3 treatments then
once weekly.
The patients underwent regular follow up and were assessed
for the local control, liver functions, renal functions, and other
events [skeletal growth asymmetry, veno-occlusive disease
(VOD), and second malignancy.
Results
Out of 17 patients treated with postoperative RT for abdomi-
nal NB, 13 patients received IMRT. At the time of starting
radiotherapy the mean age was 4.9 ± 2 years. There were 7
males and 6 females. All patients were treated for high risk dis-
ease. The radiation dose ranged from 21 to 25.5 Gy with a
mean dose of 24.06 ± 1.16, using a daily fraction 1.5–
1.8 Gy. One patient received initial 12 Gy TBI, followed by
12 Gy local abdominal RT [24 Gy total tumor dose], and the
reported RT doses were relevant to the plan sum. All other pa-
tients received no TBI. Two patients were treated with rapid
arc (RA) and 11 patients were treated with IMRT using 5–7
ﬁelds.
The PTV volume ranged from 63 to 905 cc with a median
volume of 402 cc. Table 1 summarize the volume, median of
the means dose, range of the means dose and D-max for the
PTV, liver, right and left kidneys. The median PTV for central
midline tumors was 402 [range 85–905] cc as compared to
241[range 63–581] cc for lateralized tumors.
The irradiated fractional volumes of the liver and kidneys
were compared at different dose levels, 18 Gy for the kidneys
and 15 Gy for the liver. We also looked at the V8 liver, as a
threshold dose for occurrence of VOD in transplanted pa-
tients. The mean liver volume was 529 cc, and the mean dose
was 9.81 Gy. Higher mean liver doses [up to 17.10 Gy] were ac-
cepted in individual cases, when the tumors were in close prox-
imity to the liver. The V8 of the liver was 51 ± 20% and the
V15 of the liver was 21 ± 12%.
We looked at both kidneys as bilateral structures and as
one total volume; the mean kidneys volume was 105 cc, with
a D-max of 27.06 Gy and a mean dose of 14.40+/2.65 Gy.
The V18 of both kidneys was 31 ± 13%, V18 of the right kid-
ney was 32 ± 27% and V18 of the left kidney was 23 ± 18%.
The maximum dose to the spinal cord was 23.16 Gy and the
maximum dose to the vertebrae was 24.87 Gy. The minimum
and maximum vertebral point dose was 12.82 and 24.87 Gy
Table 1 Summary of the dosimetric parameters for PTV, kidneys and liver in IMRT treated patients.
Volume (cc) Mean dose D-max
Median Range Median Range
PTV 402 63–905 24.00 21.00–25.86 27.75
Liver 541 280–767 8.71 5.64–17.10 27.75
Rt kidney 52 26–85 15.25 4.32–21.12 26.53
Lt kidney 60 25–84 12.78 8.79–18.51 27.06
Both Kidneys 102 61–156 13.80 8.85–19.66 27.06
Figure 1 DVH showing a homogenous vertebral body [VB] dose lower than the PTV dose.
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dose to the PTV and the adjacent vertebral body.
The follow up duration ranged from 1.2 to 26 months with a
median follow up of 19 months. One patient was lost to follow-
up shortly after radiotherapy. Three patients had documented
death at the time of analysis, one died 7 days post-transplant
with septic shock, and another patient died 6 months post radio-
therapy from progression of distant metastasis. The third
patient died 3 months post radiotherapy from both local and
systemic disease progression. Eight of the remaining 9 patientsTable 2 Dosimetric evaluation of 3D versus IMRT for normal tiss
Patient #1 Patient# Patien
CRT-3 Fields 1 IMRT CRT-
V2 Gy 2461 cc 2684 cc 2108
V5 Gy 2216 cc 2302 cc 1938
V10 Gy 1847 cc 1713 cc 1781
Kidney V18 Gy 80% 40% 64%
Kidney Mean 21.14 Gy 15.18 Gy 16.87
Liver Mean 12.43 Gy 10.33 Gy 9.75 G
Liver V8 Gy 58% 50% 41%
Liver V15 Gy 45% 23% 38%
a Patient 3 received 12 Gy TBI + 12 Gy local XRT, the ﬁgures represe[89%] have their local disease well controlled at the time of the
last FU.
IMRT compared to 3D-conformal RT
We evaluated the normal tissue (NT) volumes receiving 2, 5
and 10 Gy-isodose level [V2, V5, V10] for IMRT and 3-DCRT
in three patients. Table 2 shows the dosimetric comparison of
IMRT versus 3 ﬁelds CRT [patient #1&3], and IMRT versus
conventional AP/PA ﬁelds [patient #2]. The patient #3 re-ues, the kidneys and the liver (N= 3 patients).
t#2 Patient#2 Patient# 3a Patient# 3a
AP/PA IMRT CRT-3F IMRT
cc 2808 cc 2254 cc 2841 cc
cc 2095 cc 1976 cc 1984 cc
cc 1561 cc 1538 cc 792 cc
50% 61% 52%
Gy 15.88 Gy 19.80 Gy 19.66 Gy
y 8.78 Gy 20.27 Gy 18.29 Gy
44% 100% 100%
18% 72% 86%
nt sum plan.
Figure 2 DVH showing the dose to the body from two plans [m] IMRT [n] 3D.
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to post-transplant 12 Gy to the primary site for local control,
and the ﬁgures displayed are pertinent to the plan sum
[TBI + primary tumor bed]. Whereas the dose to the liver
was higher with IMRT as compared to 3D-conformal RT, a
clear dosimetric advantage could be seen for IMRT in terms
of the kidneys. Using IMRT, the kidney volume receiving
18 Gy was reduced by 20–50%, and the mean dose was mar-
ginally reduced.
RA was slightly better than IMRT in terms of PTV cover-
age and dose to the kidneys. The main advantage of RA was
reduced treatment time and faster treatment delivery, which
shortened the GA duration, since most of the patients were
treated under GA. The volume of normal tissues receiving
low dose radiation [NT = body minus PTV] was much less
with 3-DCRT as compared to IMRT, for the dose range of
2–5 Gy. This pattern was maintained until the DVHs inter-
sected at doses above 8–10 Gy (Fig. 2).
Acute toxicity
All patients received daily oral or IV Ondansetron 1 hour prior
to radiotherapy. One to two episodes of vomiting were re-
ported by ﬁve patients on the ﬁrst day of treatment as they
did not receive Ondansetron before treatment, while none of
the patients complained of vomiting with adequate medica-
tions. Skin grade I erythema was noticed in most of the pa-
tients, only two patients have developed grade II dry
desquamation after the second week of treatment. Grade 3
toxicity was not reported. None of the patients complained
of diarrhea. Grade III hematological toxicities were not seen.
Late toxicity
The follow-up period is too short for late toxicity evaluation.
At a 26 months [median 19 months] follow up period, no sec-
ond malignancy has been noted. Evaluation of the patients did
not show so far any skeletal abnormality on the FU X-rays
and CT scan. The liver functions were normal in all except 2patients who died from post transplant septic shock [ﬁrst]
and visceral metastasis [second]. The remaining 11 patients
had normal liver enzymes and bilirubin level, with mean
ALT 31 ± 26 U/L of and mean bilirubin of 7+/3 umol/L.
One patient who died from post transplant septic shock had
elevated creatinine. All of the remaining patients had normal
renal functions [mean creatinine level of 31+/15 umol/L],
and normal contrast enhancement evaluation of the kidneys
on FU CT scan.
Discussion
The radiotherapy dose for NB local control varies according to
the treatment protocol: the CCG A3973 protocol prescribes
2160 cGy, while the German NB 2004 trial advices 36–40 Gy
plus MIBG therapy. At our institution, patients with com-
pletely resected tumor received a dose of 21–24 Gy, with a
boost dose up to 36 Gy in patients with gross residual tumor,
if this could be achieved without exceeding the kidneys
tolerance.
The mean PTV for central midline tumors was 417 [range
85–905] cc as compared to 262 [range 63–581] cc for lateralized
tumors. The patients with centrally located tumors were more
prone to have larger residual disease. Because the fact that cen-
trally located tumors were often attached to or wrapping
around the major vessels and nerves, achieving a total or sub-
total resection was not possible. The large PTV added to the
complexity of RT planning and the difﬁculty of reducing the
RT dose to the kidneys in this group of patients.
Whether the PTV should include the vertebral body or not
and rather be limited to the target is one of the controversial
areas in IMRT planning for NB. To the best of our knowledge,
there exists no outcome data on late effects in the literature to
support the use of IMRT in NB. Paulino et al. compared con-
ventional to IMRT plans, with and without the vertebral body
being included in the PTV. The plan that excluded the vertebra
from PTV showed heterogeneous dose distribution over the
vertebral body with consequential unidentiﬁed long term skel-
etal side effects [9]. In this young age group of patients, doses
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scoliosis. On the other hand, including the vertebral body in
the primary PTV to doses above 20 Gy makes it very difﬁcult
to reduce the dose to the kidney. Hence, we elected to contour
the vertebral body as a secondary PTV, in order to avoid
signiﬁcant heterogeneous dose gradient across the vertebra
that could result in skeletal deformities in the future while
reducing the dose to the kidneys.
The evaluation of liver and kidney toxicities as a function of
time is a complex endpoint, since these organs may sustain
subclinical damage that may be only expressed later on. This
is particularly true for this group of transplanted children,
where the potential toxicity of high-dose chemotherapy could
be an additional contributing factor. Due to the retrospective
nature of this study we could only evaluate the toxicity based
on the kidney and liver functions, as well as the routine post-
treatment follow-up CT scan with contrast.
The potential of developing SMN is a major concern in this
young patient population. Hall and Wuu have hypothesized
that the use of IMRTwill likely result in an increase in secondary
malignancies from 1% using conventional RT to 1.75% using
IMRT for patients surviving 10 years from irradiation. This is
becausemore normal tissue is receiving lowdoseRTwith IMRT
compared to conventional RT, andmore monitor units are used
to deliver the same dose with IMRT which translates to more
radiation leakage to the entire body [10]. Hall also suggested
that children are more sensitive than adults for developing
SMN by a factor of 10. It is not possible to make conclusions
from our data on the effect of IMRT on second malignancy
due to the short duration of the follow up period. In the current
study, a dosimetric comparison of IMRT to conventional RT
for 3 NB patients is displayed in Table 2. For volumes exposed
to low-dose RT, IMRT signiﬁcantly increased the normal tissue
volume receiving 50% or less of the prescribed dose. This must
be cautiously considered when implementing IMRT in pediat-
rics, particularly with extended RT ﬁelds such as craniospinal
or mantle ﬁelds, where a signiﬁcant volume of normal tissues
would be encompassed.
Conclusions
The use of IMRT in pediatric NB confers higher conformality
to the target volume with better sparing of the kidneys, partic-
ularly in patients with centrally located tumors. This isachieved at the expense of a larger volume of normal tissues
receiving low RT dose. In this study as in others using IMRT
in pediatric and young patients, there is a need for a longer fol-
low-up for more reliable estimation of potential hazards of
IMRT with respect to late skeletal toxicity and secondary
malignancies.
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